Author

Yuwei Ren

University of Southern CaliforniaORCID 0000-0001-7610-2538Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

John Paul MuradiD· 3 shared Lea ChristianiD· 3 shared Saul J. PricemaniD· 3 shared Stephen J. FormaniD· 3 shared Cari A. YoungiD· 2 shared Catalina Martinez· 2 shared Handan Hong· 2 shared Jiangyue LiuiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

John Paul MuradORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 3, 2026

Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment

Jiangyue Liu, Iveta Fajnorovà, Yuwei Ren…·Saul J. Priceman

Combining 177Lu-PSMA-617 radioligand therapy with PSCA-CAR T cells improves tumor control and survival in prostate cancer models by overcoming antigen heterogeneity and reshaping the immunosuppressive tumor microenvironment.

DOI 10.64898/2026.07.02.736191

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJun 24, 2026

Focal radiotherapy improves CAR T cell therapy targeting prostate cancer

Cari A. Young, Jiangyue Liu, Yuwei Ren…·Saul J. Priceman

This study combines focal radiotherapy, cyclophosphamide, and PSCA-CAR T cells to enhance antitumor responses and survival in prostate cancer models.

DOI 10.64898/2026.06.23.734073

mouseexperimental assay

𝕏 PostBluesky

BioengineeringbioRxivPreprintApr 4, 2025

Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery

John Paul Murad, Lea Christian, Reginaldo Cruz Alves Rosa…·Saul J. Priceman

This study engineers CAR T cells with PDL1-IL12 fusion proteins to enhance anti-tumor responses in solid tumors by improving T cell function and reducing systemic inflammation.

DOI 10.1101/2025.04.04.647304

mouseexperimental assay

𝕏 PostBluesky